This large-scale observational study analyzed cardiovascular outcomes in 45,678 patients with metabolic syndrome treated with GLP-1 receptor agonists over a 3-year period. Using electronic health records from multiple healthcare systems, we assessed major adverse cardiovascular events (MACE) and found a 23% reduction in cardiovascular risk compared to standard care. The protective effects were most pronounced in patients with baseline cardiovascular disease.